Accelerators & startups AgriBusiness AgTech Biotech Blog Company Profiles Industry microbes Research & Data USA

Trend Continues for Ag Biologics Startups to Partner on Microbe Products

Biologics hold substantial promise for a more sustainable food system, however with hundreds of thousands of microbes to type via, startups are turning to partnerships to hunt for probably the most promising strains within the bacterial haystack.

The bio inputs area is on a speedy climb as farmers are wanting for new solutions as an alternative of the normal suite of chemical compounds that they’ve relied on for the last several many years. This new class of merchandise consists of natural crop safety and plant health solutions that can be used alone or together with a standard chemical enter program. At their core, they include specific microbes which were proven to present certain advantages to a plant, whether or not it’s helping them uptake nitrogen from the soil or helping the plant fend off pests and disease instantly or by way of the oblique production of metabolites.

There are a selection of forces driving farmers to think about bio-based options even if they continue to be skeptical about their consistency and efficacy. Environmental issues just like the unintentional creation of herbicide-resistant weeds and a lifeless zone within the Gulf of Mexico due to fertilizer runoff carried down the Mississippi River from Midwest crop nation are just some examples. Human well being considerations relating to a number of the chemical inputs which are used in meals production are also reaching new heights as Monsanto continues to battle battles in courtroom relating to glyphosate and its link to most cancers.

Joyn Bio and NewLeaf Partner on Research

While the biotechnology area is usually fraught with competitors and clandestine secrets and techniques that would unlock main progress – and income – some startups in the biologics area are starting to see that the one means to make headway via these hundreds of thousands of microbes is by becoming a member of forces.

“There are literally millions of different kinds of microbes that grow naturally. The challenge is how you make this huge number of microbes that interact with many plants and environments and that have a role in controlling plant disease and health traceable?” Tom Laurita, CEO and co-founder of NewLeaf Symbiotics, tells AFN. Laurita has just announced a partnership with Joyn Bio, the $100 million joint venture between Bayer Crop Science and microbe producer Ginkgo Bioworks.

Want to spend money on the foodtech and agtech revolution?

Be a part of Us! Enroll for our next fund right here.

Underneath the partnership, Joyn Bio could have entry to NewLeaf’s library of proprietary, highly- characterised strains of plant-colonizing microbes that it’s been constructing since 2012. It will get Joyn’s flagship nitrogen-fixing microbe on the market two to three years sooner than previously scheduled. The partnership is valued at round $75 million.

“Joyn will have an exclusive license to leverage select NewLeaf microbes for developing novel solutions that deliver a range of important benefits to plants, including nitrogen-fixation and crop protection capabilities. NewLeaf will receive an upfront payment and payments for achieved milestones throughout the agreement term,” reads the press launch.

Joyn Bio touts exclusive access to the genetic codebase and biological engineering foundries of Ginkgo Bioworks, which is concentrated on genetically engineering microbes for associate corporations in the taste, fragrance, agriculture, and food industries. Joyn Bio is engineering these microbes with the hopes of offering novel illness and pest management merchandise to farmers so that they will scale back their reliance on traditional chemical compounds.

The two businesses will proceed to market their own products with the important thing differentiator being that NewLeaf focuses on naturally-occurring microbes, while Joyn registers, markets and sells engineered options.

“A big deal in the biologics space”

NewLeaf describes itself as having deep experience and IP in genomics and production thanks to its platform, the Prescriptive Biologics Knowledgebase, which mixes nature and machine learning. This computational engine curates genotype and phenotype knowledge and predicts the efficiency of microbes from the NewLeaf’s library. For the last eight years, NewLeaf has been targeted on a selected family of microbes referred to as M-trophs, with 12,000 strands in its genomic library.

“The engineering approach that Joyn Bio has taken is extremely promising. What they do has always been something we have recognized as a revolutionary opportunity in agriculture,” Laurita explains. “It’s important to understand the value of Ginkgo Bioworks. Its technology brings an extremely efficient method of assaying engineered microbes and that’s something we don’t have and that we can’t build.”

For Joyn Bio, having access to the library of M-trophs and being able to understand which strains have probably the most potential as crop inputs is simply as invaluable.

“This partnership gives Joyn Bio access to these highly characterized M-trophs that NewLeaf has spent so much time developing. It’s great for us to get access to these as host or chassis microbes and it gives NewLeaf the opportunity to see if their host microbes are going to be useful,” Mike Miille, Joyn Bio CEO, additionally advised AFN.

With NewLeaf targeted on naturally-occurring microbes and Joyn Bio targeted on engineering microbes to optimize efficiency, one may think that the partnership is an unlikely pairing. However contemplating the dimensions of the market opportunity and regulatory roadblocks that would develop in certain areas opposed to genetic engineering, the duo is actually simply overlaying all of the bases.

“Each company has a clearly defined role. This is a big deal in the biologics space. We are two of the most science-based, serious, forward-working, and well-financed companies in the space. The fact that we are joining together is really quite a statement in the industry,” Laurita says.

Regulation & Social License for GM Microbes

Sure markets in Europe and different geographies that instituted outright bans on the cultivation of GMOs might take an identical strategy to genetically engineered microbes, for example, leaving the door large open for merchandise based mostly on naturally occurring microbes. And in some instances, the pure product may be higher suited for the task, Miille believes.

“There are plenty of targets out there and some may be best handled with a naturally occurring microbe that evolved to do something with the plant, and in other cases, the natural product probably won’t be as effective as the engineered microbe. I see room for both of these approaches in the market and that’s another reason we are working with Joyn Bio,” Laurita provides. “They can do things we won’t and we will do things that they won’t.”

There’s, in fact, the other activity of obtaining social license as nicely. If the GMO period has taught biotechnologists and entrepreneurs something, it’s that a lack of public approval can have a damning impact whatever the know-how’s proven potential within the lab.

With a lot current consideration around the significance of gut well being and the position of the microbiome in human well being, nevertheless, parlaying the potential benefits of manipulating microbes for crop health could possibly be a pure and logical leap for many shoppers. However as Miille factors out, any time a genetically engineered product nears the market, it’s greatest to take a proactive as opposed to a reactive strategy.

“You have to assume there are going to be challenges and people who are anti-GMO that will be anti-anything. The best way to address this challenge is through education and communication and by making people aware that you have done all of the safety studies and that you can articulate the benefits of what you are bringing to market at an emotional level versus arguing about the science,” he explains. “We have learned that you have to start now – three or four years before the product comes out – to get people comfortable with the concept.”

For genetically engineered microbial crop inputs, subsequently, the bar is about as excessive because it will get. Not solely do corporations aiming for commercialization have to quell any shopper misgivings, they need to also prove themselves as effective as conventional chemical inputs when it comes to preventing illness and pest strain or boosting yield.

“That’s a big challenge,” Miille says, “We have to demonstrate how much an engineered microbe can work relative to a natural microbe. The target we gave ourselves is that if these are for pest or disease control, we want those microbial products to work at the same level or even better than the current chemical standard. It’s not good enough to say that we want to work as well as the natural biologic products. We have to set a much higher target.”

Biologics Partnerships on the Rise to Meet Challenges

After getting by way of the challenge of researching and discovering the most effective microbes for the job, getting them into farmers’ arms is one other main headwind for these teams. Farmers have been skeptical about biologics and their efficacy.

“Partnerships are increasing among biological companies. This trend will continue,” Pam Marrone, CEO and founder of Marrone Bio Innovations and a veteran within the biologics area, wrote to AFN. “There is a new crop of startup companies that have enabling technologies such as formulation technology to increase the efficacy of biologicals and we have several collaborations in this arena. We also just announced a collaboration with Valagro on new biostimulants. A small company like ours can’t do everything so small companies can leverage each others’ technologies to joint benefit.”

Breaking down many farmers’ initial skepticism over whether microbes can work just as well as chemical compounds is oftentimes the first and most difficult step. The production cycle in commodity crop agriculture is a limiting issue, the place farmers only have one opportunity each season to trial new merchandise. With farm income as slim as ever, risking this yr’s revenue on a completely new class of enter is an enormous ask.

There are additionally the basic set of challenges that has confronted every bio-based inputs company, including how to mass-produce a temperature-sensitive, dwelling bacterial product whereas attaining the same degree of consistency and efficacy that farmers have grown accustomed to in traditional chemical inputs. Lots of NewLeaf’s patents focus on these downstream obstacles surrounding production, Laurita explains.

3Bar and microbial input startup Pivot Bio have also partnered lately to attempt to remedy a few of these challenges. Pivot Bio has developed a nitrogen-producing microbial product referred to as PROVEN that fixates nitrogen from the environment and secretes it on the corn crop’s root zone to be used when the plant wants it. But maybe more necessary than the science involved is the packaging and delivery mechanism of those microbes, which 3Bar supplies; chief complaints from farmers about biologics embrace integrating the merchandise with present gear and packages as well as efficacy, and inconsistent results.

3Bar’s supply system allows a farmer to cultivate a recent batch of microbes proper on the farm or at residence by pushing a button on the surface of the field, starting the bacterial fermentation process. Every little thing the microbes want to develop is situated inside and the farmer does not have to perform any contamination protocols like sanitizing his or her arms earlier than beginning the method. Inside 24-48 hours, the microbes are ready for use but they are often stored inside the field for up to three weeks. This can be a key window for farmers who might have a sudden change of plans due to on-farm emergencies or a sudden unpredicted change within the weather.